Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) VP Michael S. Aberman sold 3,611 shares of the company’s stock on the open market in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $350.00, for a total transaction of $1,263,850.00. Following the completion of the sale, the vice president now directly owns 15,600 shares of the company’s stock, valued at approximately $5,460,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

REGN has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Regeneron Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $345.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.76% on Tuesday, hitting $346.79. 467,657 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52-week low of $227.97 and a 52-week high of $353.05. The stock’s 50-day moving average is $319.2 and its 200-day moving average is $309.6. The company has a market cap of $34.814 billion and a P/E ratio of 99.45.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the prior year, the company posted $1.73 earnings per share. The company’s quarterly revenue was up 45.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $10.14 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.